MX2024009976A - Composicion farmaceutica que comprende anticuerpo anti-tigit y anticuerpo bispecifico anti-pd-1/anti-vegfa y su uso. - Google Patents
Composicion farmaceutica que comprende anticuerpo anti-tigit y anticuerpo bispecifico anti-pd-1/anti-vegfa y su uso.Info
- Publication number
- MX2024009976A MX2024009976A MX2024009976A MX2024009976A MX2024009976A MX 2024009976 A MX2024009976 A MX 2024009976A MX 2024009976 A MX2024009976 A MX 2024009976A MX 2024009976 A MX2024009976 A MX 2024009976A MX 2024009976 A MX2024009976 A MX 2024009976A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- tigit
- vegfa
- pharmaceutical composition
- composition including
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210132762.1A CN114181310B (zh) | 2022-02-14 | 2022-02-14 | 抗tigit抗体、其药物组合物及用途 |
| PCT/CN2023/075862 WO2023151693A1 (zh) | 2022-02-14 | 2023-02-14 | 包含抗tigit抗体和抗pd-1-抗vegfa双特异性抗体的药物组合物及用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009976A true MX2024009976A (es) | 2024-08-26 |
Family
ID=80607015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009976A MX2024009976A (es) | 2022-02-14 | 2023-02-14 | Composicion farmaceutica que comprende anticuerpo anti-tigit y anticuerpo bispecifico anti-pd-1/anti-vegfa y su uso. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250034253A1 (https=) |
| EP (1) | EP4273170A4 (https=) |
| JP (1) | JP2025506318A (https=) |
| KR (1) | KR20240145470A (https=) |
| CN (1) | CN114181310B (https=) |
| AU (1) | AU2023217806A1 (https=) |
| CA (1) | CA3208430A1 (https=) |
| IL (1) | IL314785A (https=) |
| MX (1) | MX2024009976A (https=) |
| WO (1) | WO2023151693A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020324185A1 (en) * | 2019-08-02 | 2022-03-03 | CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. | Anti-PD-1 antibody and medical use thereof |
| IL310217A (en) * | 2021-07-23 | 2024-03-01 | Akeso Biopharma Inc | Pharmaceutical composition and use |
| AU2022330896A1 (en) * | 2021-08-20 | 2024-02-22 | Akeso Biopharma, Inc. | FUSION PROTEIN CONTAINING ANTI-TIGIT ANTIBODY AND TGF-βR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| CN114181310B (zh) * | 2022-02-14 | 2022-07-05 | 中山康方生物医药有限公司 | 抗tigit抗体、其药物组合物及用途 |
| CN116284395B (zh) * | 2022-12-12 | 2024-11-08 | 合肥天港免疫药物有限公司 | 抗cd155的抗体及其应用 |
| CN116143923B (zh) * | 2022-12-30 | 2025-11-11 | 合肥天港免疫药物有限公司 | 高亲和力tigit抗体及其应用 |
| JP2026508210A (ja) * | 2023-02-20 | 2026-03-10 | 中山康方生物医▲藥▼有限公司 | ＴＧＦ－βＲＩＩ細胞外領域断片を含む融合タンパク質、その医薬組成物、およびその使用 |
| CN119613559B (zh) * | 2023-09-14 | 2026-01-02 | 中山康方生物医药有限公司 | 药物组合及用途 |
| CN120530139A (zh) * | 2023-12-29 | 2025-08-22 | 成都优洛生物科技有限公司 | 抗tl1a抗体或其抗原结合片段及应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| CN101355965A (zh) * | 2005-06-08 | 2009-01-28 | 达纳－法伯癌症研究院 | 通过抑制程序性细胞死亡1（pd-1）途经治疗持续性感染和癌症的方法及组合物 |
| AU2009333580B2 (en) * | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| KR102236367B1 (ko) | 2013-07-26 | 2021-04-05 | 삼성전자주식회사 | DARPin을 포함하는 이중 특이 키메라 단백질 |
| US10323095B2 (en) | 2014-03-17 | 2019-06-18 | Mitsubishi Tanabe Pharma Corporation | Antibody-fynomer conjugates |
| AU2015305754B2 (en) * | 2014-08-19 | 2018-10-25 | Merck Sharp & Dohme Llc | Anti-tigit antibodies |
| CA2994858C (en) | 2015-09-25 | 2024-01-23 | Genentech, Inc. | Anti-tigit antibodies and methods of use |
| RS64576B1 (sr) * | 2017-05-01 | 2023-10-31 | Agenus Inc | Anti-tigit antitela i postupci njihove primene |
| US11512129B2 (en) * | 2017-09-29 | 2022-11-29 | Jiangsu Hengrui Medicine Co., Ltd. | TIGIT antibody, antigen-binding fragment thereof, and medical use thereof |
| CN109053895B (zh) * | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| CN111196852A (zh) * | 2018-11-16 | 2020-05-26 | 四川科伦博泰生物医药股份有限公司 | 抗tigit抗体及其用途 |
| US20230027029A1 (en) * | 2019-11-25 | 2023-01-26 | Akeso Biopharma, Inc. | Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof |
| CN110960543A (zh) * | 2019-12-10 | 2020-04-07 | 安徽瀚海博兴生物技术有限公司 | 一种联合抗vegf-抗pd1双特异性抗体用于制备抗癌药物 |
| TWI813934B (zh) * | 2020-01-21 | 2023-09-01 | 大陸商甫康（上海）健康科技有限責任公司 | 一種雙特異性抗pd-l1/vegf抗體及其用途 |
| CN115315256A (zh) * | 2020-01-27 | 2022-11-08 | 基因泰克公司 | 用抗tigit拮抗剂抗体治疗癌症的方法 |
| WO2021263085A2 (en) * | 2020-06-25 | 2021-12-30 | Arch Oncology, Inc. | Combination therapy for the treatment of solid and hematological cancers |
| EP4192883A4 (en) * | 2020-08-05 | 2024-12-04 | Crystal Bioscience Inc. | Anti-tigit antibody and methods of use thereof |
| US11028172B1 (en) * | 2020-11-10 | 2021-06-08 | Lepu Biopharma Co., Ltd. | Anti-TIGIT antibodies and uses thereof |
| CN114181310B (zh) * | 2022-02-14 | 2022-07-05 | 中山康方生物医药有限公司 | 抗tigit抗体、其药物组合物及用途 |
-
2022
- 2022-02-14 CN CN202210132762.1A patent/CN114181310B/zh active Active
-
2023
- 2023-02-14 IL IL314785A patent/IL314785A/en unknown
- 2023-02-14 US US18/264,138 patent/US20250034253A1/en active Pending
- 2023-02-14 JP JP2023547446A patent/JP2025506318A/ja active Pending
- 2023-02-14 KR KR1020247026551A patent/KR20240145470A/ko active Pending
- 2023-02-14 CA CA3208430A patent/CA3208430A1/en active Pending
- 2023-02-14 AU AU2023217806A patent/AU2023217806A1/en active Pending
- 2023-02-14 MX MX2024009976A patent/MX2024009976A/es unknown
- 2023-02-14 EP EP23745373.3A patent/EP4273170A4/en active Pending
- 2023-02-14 WO PCT/CN2023/075862 patent/WO2023151693A1/zh not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4273170A4 (en) | 2025-02-19 |
| WO2023151693A1 (zh) | 2023-08-17 |
| EP4273170A1 (en) | 2023-11-08 |
| CN114181310B (zh) | 2022-07-05 |
| KR20240145470A (ko) | 2024-10-07 |
| CA3208430A1 (en) | 2023-08-14 |
| US20250034253A1 (en) | 2025-01-30 |
| CN114181310A (zh) | 2022-03-15 |
| AU2023217806A1 (en) | 2024-09-12 |
| JP2025506318A (ja) | 2025-03-11 |
| IL314785A (en) | 2024-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024009976A (es) | Composicion farmaceutica que comprende anticuerpo anti-tigit y anticuerpo bispecifico anti-pd-1/anti-vegfa y su uso. | |
| ES2543174T3 (es) | Composición medicinal para el tratamiento y/o la prevención del cáncer | |
| PH12021550023A1 (en) | Humanized anti-tau antibodies | |
| AR117727A1 (es) | Anticuerpos que se unen a cd3 | |
| PE20241170A1 (es) | Anticuerpo triespecifico dirigido a bcma, gprc5d, y cd3 | |
| CL2021002966A1 (es) | Combinación de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento del cancer. | |
| PE20230160A1 (es) | Anticuerpos especificos para cd47, pd-l1 y sus usos | |
| AR105313A1 (es) | Anticuerpo anti-cd137 terapéutico | |
| AR104280A1 (es) | Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos | |
| CL2020003256A1 (es) | Métodos para el tratamiento del cáncer con anticuerpos anti-cd3xmuc16 y anticuerpos anti-pd-1 biespecíficos. | |
| MX2024001067A (es) | Composicion farmaceutica y uso. | |
| PE20181076A1 (es) | Nuevos moduladores y metodos para su uso | |
| CL2015001895A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| ZA202305217B (en) | Anti-tigit antibody, and pharmaceutical composition and use thereof | |
| CL2020002600A1 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
| PE20121494A1 (es) | Anticuerpos anti notch-1 | |
| MX2024004216A (es) | Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb. | |
| AR126154A1 (es) | Agentes aglutinantes biespecíficos que se unen a cldn18.2 y cd3 | |
| MX2024010334A (es) | Composicion farmaceutica que comprende anticuerpo biespecifico anti-ctla4-anti-pd-1 y chiauranib. | |
| MX2022012913A (es) | Anticuerpo anti-ox40 y usos del mismo. | |
| AR123671A1 (es) | Anticuerpo fn14 anti-humano | |
| CL2024002975A1 (es) | Anticuerpo biespecífico anti-tigit y anti-pvrig, composición farmacéutica del mismo, y uso del mismo | |
| PE20191743A1 (es) | Anticuerpos biespecificos anti-pd-l1-anti-tim3 | |
| AR121441A1 (es) | Anticuerpos anti-axl y composiciones | |
| MX2020003806A (es) | Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer. |